VelaDx Licenses Swift Bio's Primer Technology for PCR-based Dx | GenomeWeb

NEW YORK (GenomeWeb News) – Swift Biosciences announced today a licensing deal with Vela Operations for the rights to Swift's myT Primer Technology.

The terms of the agreement give Vela Diagnostics the non-exclusive rights to use Swift's technology in Vela's real-time quantitative PCR-based IVD products for detecting somatic mutations in human cancer. Vela will seek regulatory approval for the assay kits globally and Swift will develop myT Primers for research-use only applications.

Further terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.